Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Payables: 2020-2025

Historic Payables for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $38.6 million.

  • Apellis Pharmaceuticals' Payables fell 9.66% to $38.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $186.7 million, marking a year-over-year increase of 28.49%. This contributed to the annual value of $38.6 million for FY2024, which is 2.81% up from last year.
  • Apellis Pharmaceuticals' Payables amounted to $38.6 million in Q3 2025, which was down 28.83% from $54.2 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Payables ranged from a high of $55.3 million in Q1 2025 and a low of $4.2 million during Q1 2021.
  • For the 3-year period, Apellis Pharmaceuticals' Payables averaged around $37.2 million, with its median value being $38.3 million (2024).
  • Its Payables has fluctuated over the past 5 years, first crashed by 54.97% in 2021, then spiked by 203.80% in 2022.
  • Apellis Pharmaceuticals' Payables (Quarterly) stood at $16.9 million in 2021, then spiked by 120.84% to $37.3 million in 2022, then grew by 0.47% to $37.5 million in 2023, then climbed by 2.81% to $38.6 million in 2024, then fell by 9.66% to $38.6 million in 2025.
  • Its last three reported values are $38.6 million in Q3 2025, $54.2 million for Q2 2025, and $55.3 million during Q1 2025.